2Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus[J]. N Engl J Meal, 1995, 333(9): 550-554.
3Zbou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action[J]. J Clin Invest, 2001, 108(8): 1167- 1174.
4Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP- 1) enhancer and sensitizer[J]. Diabetologia, 2011, 54(2): 219-222.
5Herrnann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination[J]. Diabet Med, 1994, 11(10): 953-960.
6Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes[J]. Diabetes Care, 1996, 19(1): 64-66.
7Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose- response trial[J]. Am J Med, 1997, 103(6): 491-497.
8Peter Timmins, Steve Donahue, Jeff Meeker, et al. Steady-state pharmacokinetics of a novel extended-rrelease metformin formulation[J]. Clin Pharmacokinet, 2005, 44(7): 721-729.
9Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin(Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo- controlled studies[J]. Diabetes Obes Metab, 2005, 7(1): 28-39.
4Taal MW, Chertow GM, Marsden PA, el al. Brenner c. Ree tor's The Kidney. 9th ed. Philadelphia, PA= Saunders Elsevi- er, 2012.
5Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China N Engl J Med, 2010,362:1090-1101.
6Fox CS, Larson MG, I.eip EP, et al. Predictors of new-onset kidney disease in a community based population. JAMA,2004, 291 : 84,1-850.
7Zhang 1., Zhang P, Wang F, et al. Prevalence and factors as- sociated with CKD: a population study from Beijing. Am J Kid- ney Dis, 2008, 51:373-384.
8Zhang L, Wang F, Wang L, et al. Prevalence of chronic kid- ney disease in China: a cross sectional survey, Lancei, 2012, 379:815-822.
9National Kidney Foundation. KI)O'QI Clinical practice guide- lines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis, 2007,49(suppl 2): S1 -S180.
10Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diahetes mellitus in the United States. Clin Ther, 2009, 31:2608-2617.
2The Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group.Revised 2003consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome[J].Fertil Steril, 2004, 81(1): 19-25.
3Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al.Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome[J].J Clin Endocrinol Metab, 2008, 93(7): 2670-2678.
4Garber AJ, Duncan TG, Goodman AM, et al.Efficacy of metformin in type Ⅱ diabetes: results of a double-blind, placebo-controlled, dose-response trial fn1[J].Am J Med, 1997, 103(6): 491-497.
